Denikitug
Phase 2Small molecule
GileadDenikitug is one of 6 small molecule programs targeting HER2-Negative. It is currently in Phase 2.
2
Indications
3
Total Trials
3
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
3 competitors in Advanced Microsatellite Stable Colorectal Cancer
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 2
Avastin
BBio-Thera Solutions
Phase 2
Trifluridine-Tipiracil
Merck & Co.Phase 2
Denikitug
GileadPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Solid Tumors1 trial
HER2-Negative1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Denikitug. EMBL-EBI & Wellcome Sanger Institute.
- [4]